Description
The Market for Inherited Disease Molecular Diagnostic Testing
The detection of single nucleotide polymorphisms (SNPs) or gene variants from tissue, blood, urine and saliva samples can be used to diagnose inherited diseases and genetic disorders as well as determine the risk of disease manifestation or progression. Point mutations in genomic DNA occur when a single nucleotide (A,T,C, or G) sequence is altered. Many SNPs have no effect on cell function, but scientists believe others could predispose people to disease or influence their response to a drug. Although more than 99% of human DNA sequences are the same, variations in DNA sequence can have a major impact on how humans respond to disease, environmental factors (e.g. bacteria, viruses, toxins, and chemicals), and drugs or other therapies. Although a relatively stable area of clinical molecular testing, SNP analysis in patient pools and populations is an area of intense engagement in translational research. This report covers markets for testing for inherited diseases using molecular technologies such as NGS or PCR.
Table of Contents
1: EXECUTIVE SUMMARY
INTRODUCTION
MOLECULAR DIAGNOSTIC TECHNOLOGIES
MOLECULAR DIAGNOSTICS IN HEALTHCARE
GLOBAL MOLECULAR DIAGNOSTICS MARKET
INHERITED DISEASES MARKET.
Table: 1-1
Global Molecular Diagnostics Market in Inherited Diseases (2016-2021) – United States, Europe, Rest of World ($ millions)
CONCLUSIONS
2: KEY COMPETITORS IN INHERITED DISEASE MOLECULAR DIAGNOSTICS
AMBRY GENETICS CORP.
ASURAGEN INC.
GENMARK DIAGNOSTICS
Table 2-1: GenMark Diagnostics Revenue (2013-2016) ($ millions)
ILLUMINA
Table 2-2: Illumina Revenue (2013-2016) ($ millions)
Sequencing
Translational Research
Clinical Assay Development
Industry Lab-Developed Tests
Arrays
RAINDANCE TECHNOLOGIES, INC.
ROCHE DIAGNOSTICS
Table 2-3: Roche Diagnostics Revenue (2013-2016) ($ millions)
Molecular Diagnostics
Blood Screening
Sequencing
Liquid Biopsy
Microbiology
THERMO FISHER SCIENTIFIC
Table 2-4: Thermo Fisher Scientific Revenue (2013-2016) ($ millions)
Transplant Diagnostics
qPCR
Sequencing
3: MOLECULAR DIAGNOSTICS IN HEALTHCARE
INTRODUCTION
REIMBURSEMENT ENVIRONMENT FOR MOLECULAR DIAGNOSTICS
MOLECULAR DIAGNOSTICS AND THE CLINICAL UTILITY STANDARD
LABORATORY-DEVELOPED TESTS ARE HERE TO STAY
CONCLUSIONS
3: MARKET FOR MOLECULAR DIAGNOSTICS IN INHERITED DISEASES
MARKET ANALYSIS
Table 9-1
Global Molecular Diagnostics Market in Inherited Diseases (2016-2021) – United States, Europe, Rest of World ($ millions)
Figure 3-1 Global Molecular Diagnostics Market in Inherited Diseases (2016) – United States, Europe, Rest of World ($ millions)
Figure 3-2 Global Molecular Diagnostics Market in Inherited Diseases (2016-2021) – United States, Europe, Rest of World ($ millions)
THROMBOPHILIA AND COAGULATION MARKERS
AUTISM
ALZHEIMER’S DISEASE
CARDIOVASCULAR DISEASE
DIABETES
PSYCHIATRIC DISORDERS
GASTROINTESTINAL CONDITIONS
OTHER AUTOIMMUNE DISEASES
CONCLUSIONS
